Cariprazine + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jun 6, 2019 → Dec 15, 2026
NCT ID
NCT03817502About Cariprazine + Placebo
Cariprazine + Placebo is a phase 3 stage product being developed by Richter Gedeon for Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03817502. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03817502 | Phase 3 | Recruiting |
| NCT01104779 | Phase 3 | Completed |
| NCT01058668 | Phase 3 | Completed |
| NCT01058096 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia